Bioavailability, In-Vivo, Licensing and Production

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Bioavailability

In-Vivo

Licensing

Production

Betta to commercialise C4 Therapeutics’ CFT8919 in greater China

Pharmaceutical Technology

MAY 31, 2023

C4 Therapeutics has entered an exclusive licensing agreement with Betta Pharmaceuticals to develop and commercialise CFT8919 across the greater China region. CFT8919 is an orally bioavailable BiDAC degrader designed to exhibit potent and selective activity against EGFR L858R in patients with non-small cell lung cancer (NSCLC).

Bioavailability

Bioavailability In-Vivo In-Vitro Licensing

Innovative Companies Diving into The Neuro Market Ahead of 2021

The Pharma Data

DECEMBER 9, 2020

Atlas cofounded, seeded and incubated Vigil, with pre-clinical stage assets in-licensed from Amgen Inc., The company plans to do this by developing drugs that eliminate protein aggregation by either reducing the production of toxic proteins or removing them after the fact through autophagy. which will remain a key shareholder.

Marketing

Marketing In-Vivo Protein In-Vitro

Clinical Research Informer

Betta to commercialise C4 Therapeutics’ CFT8919 in greater China

Innovative Companies Diving into The Neuro Market Ahead of 2021

Stay Connected